Skip to main content

Influenza, Human

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
NCT05875961 | PHASE 1 | INTERVENTIONAL

This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine. Approximately 600 healthy adult subjects are to be randomized into 1 of 6 possible treatment groups with 100 subjects per group, stratified by age group (born after or before 1968). Each subject will receive an influenza vaccine injection on Day 1 and Day 22. Subjects will be followed up for approximately 12 months after the second vaccine injection. The primary immunogenicity analysis is based on the Day 1, Day 8, Day 22, Day 29, and Day 43 serology data. The primary safety analysis is based on solicited local and systemic adverse events (AEs) reported within 10 days after each vaccination, unsolicited AEs reported within 3 weeks after each vaccination, and serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal from the study, and AEs of special interest (AESIs) reported throughout the study.

Trial Information
7 Sites
600 Participants
Recruiting
18 Years to 47 Months

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Meridian Clinical Research
Rockville,Maryland,United States,20854
Meridian Clinical Research
Lincoln,Nebraska,United States,68510
Meridian Clinical Research
Omaha,Nebraska,United States,58134
West Visayas State University Medical Center
Iloilo City,Philippines
Manila Doctors Hospital
Manila,Philippines
Quirino Memorial Medical Center
Quezon City,Philippines
Silang Specialists Medical Center
Silang,Philippines

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov